Effects of edaravone, a radical scavenger, on hepatocyte transplantation

Chihiro Hayashi, Masahiro Ito, Ryoutaro Ito, Akiko Murakumo, Naoki Yamamoto, Noriko Hiramatsu, Ira J. Fox, Akihiko Horiguchi

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Methods Edaravone (3 mg/kg) was administered intravenously 24 h before HTx to Nagase analbuminemic rats (NARs). Hepatocytes were isolated, and 30 × 106 cells were injected in a 1.0-ml volume directly into the spleens of NARs. All experimental groups studied received FK506 to control rejection. Animals in Group A received medium-only; Group B received HTx only; and Group C received HTx and edaravone. Forty-eight hours after transplantation, the hepatocytes from animals were isolated and analyzed for staining with propidium iodide- and annexin-V using flow cytometry. Liver sections were also studied by immunostaining for albumin, and TUNEL. Peripheral blood serum albumin levels were measured on post-transplant days 0, 3, 5, 7, 10 and 14 using ELISA.

Background Hepatocyte transplantation (HTx) has yielded significant improvements in liver function and survival in experimentally induced acute liver failure and liver-based metabolic disease. However, transplantation is inefficient, and it is thought that transplanted hepatocytes have a shortened lifespan because of inflammation involving excess nitric oxide (NO). The present study aimed to clarify whether edaravone, a free radical scavenger used to treat ischemic stroke, could reduce ischemic changes in hepatocyte-transplanted livers.

Results The edaravone-treated animals demonstrated an increased number of engrafted donor hepatocytes in the liver. The edaravone-treated liver sections also contained fewer TUNEL-positive cells and animals that received edaravone had higher serum albumin levels post-transplantation. Hepatocytes were also found to have increased in numbers 2 weeks following treatment with edaravone.

Conclusions Edaravone administration during HTx can suppress apoptosis near the transplanted cells, increasing engraftment. These studies indicate its potential usefulness for future clinical application.

Original languageEnglish
Pages (from-to)919-924
Number of pages6
JournalJournal of Hepato-Biliary-Pancreatic Sciences
Volume21
Issue number12
DOIs
Publication statusPublished - 01-01-2014

Fingerprint

Hepatocytes
Transplantation
Liver
Acetylglucosaminidase
In Situ Nick-End Labeling
Serum Albumin
Free Radical Scavengers
Acute Liver Failure
phenylmethylpyrazolone
Propidium
Annexin A5
Metabolic Diseases
Tacrolimus
Albumins
Flow Cytometry
Nitric Oxide
Spleen
Enzyme-Linked Immunosorbent Assay
Stroke
Apoptosis

All Science Journal Classification (ASJC) codes

  • Surgery
  • Hepatology

Cite this

Hayashi, Chihiro ; Ito, Masahiro ; Ito, Ryoutaro ; Murakumo, Akiko ; Yamamoto, Naoki ; Hiramatsu, Noriko ; Fox, Ira J. ; Horiguchi, Akihiko. / Effects of edaravone, a radical scavenger, on hepatocyte transplantation. In: Journal of Hepato-Biliary-Pancreatic Sciences. 2014 ; Vol. 21, No. 12. pp. 919-924.
@article{8a02db3567484a0ab084892490126ba5,
title = "Effects of edaravone, a radical scavenger, on hepatocyte transplantation",
abstract = "Methods Edaravone (3 mg/kg) was administered intravenously 24 h before HTx to Nagase analbuminemic rats (NARs). Hepatocytes were isolated, and 30 × 106 cells were injected in a 1.0-ml volume directly into the spleens of NARs. All experimental groups studied received FK506 to control rejection. Animals in Group A received medium-only; Group B received HTx only; and Group C received HTx and edaravone. Forty-eight hours after transplantation, the hepatocytes from animals were isolated and analyzed for staining with propidium iodide- and annexin-V using flow cytometry. Liver sections were also studied by immunostaining for albumin, and TUNEL. Peripheral blood serum albumin levels were measured on post-transplant days 0, 3, 5, 7, 10 and 14 using ELISA.Background Hepatocyte transplantation (HTx) has yielded significant improvements in liver function and survival in experimentally induced acute liver failure and liver-based metabolic disease. However, transplantation is inefficient, and it is thought that transplanted hepatocytes have a shortened lifespan because of inflammation involving excess nitric oxide (NO). The present study aimed to clarify whether edaravone, a free radical scavenger used to treat ischemic stroke, could reduce ischemic changes in hepatocyte-transplanted livers.Results The edaravone-treated animals demonstrated an increased number of engrafted donor hepatocytes in the liver. The edaravone-treated liver sections also contained fewer TUNEL-positive cells and animals that received edaravone had higher serum albumin levels post-transplantation. Hepatocytes were also found to have increased in numbers 2 weeks following treatment with edaravone.Conclusions Edaravone administration during HTx can suppress apoptosis near the transplanted cells, increasing engraftment. These studies indicate its potential usefulness for future clinical application.",
author = "Chihiro Hayashi and Masahiro Ito and Ryoutaro Ito and Akiko Murakumo and Naoki Yamamoto and Noriko Hiramatsu and Fox, {Ira J.} and Akihiko Horiguchi",
year = "2014",
month = "1",
day = "1",
doi = "10.1002/jhbp.164",
language = "English",
volume = "21",
pages = "919--924",
journal = "Journal of Hepato-Biliary-Pancreatic Sciences",
issn = "1868-6974",
publisher = "Springer Verlag",
number = "12",

}

Effects of edaravone, a radical scavenger, on hepatocyte transplantation. / Hayashi, Chihiro; Ito, Masahiro; Ito, Ryoutaro; Murakumo, Akiko; Yamamoto, Naoki; Hiramatsu, Noriko; Fox, Ira J.; Horiguchi, Akihiko.

In: Journal of Hepato-Biliary-Pancreatic Sciences, Vol. 21, No. 12, 01.01.2014, p. 919-924.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of edaravone, a radical scavenger, on hepatocyte transplantation

AU - Hayashi, Chihiro

AU - Ito, Masahiro

AU - Ito, Ryoutaro

AU - Murakumo, Akiko

AU - Yamamoto, Naoki

AU - Hiramatsu, Noriko

AU - Fox, Ira J.

AU - Horiguchi, Akihiko

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Methods Edaravone (3 mg/kg) was administered intravenously 24 h before HTx to Nagase analbuminemic rats (NARs). Hepatocytes were isolated, and 30 × 106 cells were injected in a 1.0-ml volume directly into the spleens of NARs. All experimental groups studied received FK506 to control rejection. Animals in Group A received medium-only; Group B received HTx only; and Group C received HTx and edaravone. Forty-eight hours after transplantation, the hepatocytes from animals were isolated and analyzed for staining with propidium iodide- and annexin-V using flow cytometry. Liver sections were also studied by immunostaining for albumin, and TUNEL. Peripheral blood serum albumin levels were measured on post-transplant days 0, 3, 5, 7, 10 and 14 using ELISA.Background Hepatocyte transplantation (HTx) has yielded significant improvements in liver function and survival in experimentally induced acute liver failure and liver-based metabolic disease. However, transplantation is inefficient, and it is thought that transplanted hepatocytes have a shortened lifespan because of inflammation involving excess nitric oxide (NO). The present study aimed to clarify whether edaravone, a free radical scavenger used to treat ischemic stroke, could reduce ischemic changes in hepatocyte-transplanted livers.Results The edaravone-treated animals demonstrated an increased number of engrafted donor hepatocytes in the liver. The edaravone-treated liver sections also contained fewer TUNEL-positive cells and animals that received edaravone had higher serum albumin levels post-transplantation. Hepatocytes were also found to have increased in numbers 2 weeks following treatment with edaravone.Conclusions Edaravone administration during HTx can suppress apoptosis near the transplanted cells, increasing engraftment. These studies indicate its potential usefulness for future clinical application.

AB - Methods Edaravone (3 mg/kg) was administered intravenously 24 h before HTx to Nagase analbuminemic rats (NARs). Hepatocytes were isolated, and 30 × 106 cells were injected in a 1.0-ml volume directly into the spleens of NARs. All experimental groups studied received FK506 to control rejection. Animals in Group A received medium-only; Group B received HTx only; and Group C received HTx and edaravone. Forty-eight hours after transplantation, the hepatocytes from animals were isolated and analyzed for staining with propidium iodide- and annexin-V using flow cytometry. Liver sections were also studied by immunostaining for albumin, and TUNEL. Peripheral blood serum albumin levels were measured on post-transplant days 0, 3, 5, 7, 10 and 14 using ELISA.Background Hepatocyte transplantation (HTx) has yielded significant improvements in liver function and survival in experimentally induced acute liver failure and liver-based metabolic disease. However, transplantation is inefficient, and it is thought that transplanted hepatocytes have a shortened lifespan because of inflammation involving excess nitric oxide (NO). The present study aimed to clarify whether edaravone, a free radical scavenger used to treat ischemic stroke, could reduce ischemic changes in hepatocyte-transplanted livers.Results The edaravone-treated animals demonstrated an increased number of engrafted donor hepatocytes in the liver. The edaravone-treated liver sections also contained fewer TUNEL-positive cells and animals that received edaravone had higher serum albumin levels post-transplantation. Hepatocytes were also found to have increased in numbers 2 weeks following treatment with edaravone.Conclusions Edaravone administration during HTx can suppress apoptosis near the transplanted cells, increasing engraftment. These studies indicate its potential usefulness for future clinical application.

UR - http://www.scopus.com/inward/record.url?scp=84912062622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84912062622&partnerID=8YFLogxK

U2 - 10.1002/jhbp.164

DO - 10.1002/jhbp.164

M3 - Article

C2 - 25205207

AN - SCOPUS:84912062622

VL - 21

SP - 919

EP - 924

JO - Journal of Hepato-Biliary-Pancreatic Sciences

JF - Journal of Hepato-Biliary-Pancreatic Sciences

SN - 1868-6974

IS - 12

ER -